Navigation Links
Rabbit Anti-gp120/160(SIV/mac239) Polyclonal Antibody, Unconjugated from Immune Technology

ProductsRabbit Anti-gp120/160(SIV/mac239) Polyclonal Antibody, Unconjugated from Immune Technology
Company Immune Technology
Item Rabbit Anti-gp120/160(SIV/mac239) Polyclonal Antibody, Unconjugated
Price $225.00
Description Anti-gp120/160(SIV/mac239)
Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)
Info Immune Technology
34-25 69th Street
Woodside, NY 11377
Customer Service: 866-448-8878
Fax Number: 718-907-7961
Web Site: http://www.immune-tech.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Rabbit Anti-Aph-1aL, S Loop (92-115) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc
2. Rabbit Anti-Human Vitamin K-dependent Protein S (PROS1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
3. Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
4. Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
5. Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
6. Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
7. MaxArray Tissue Array (Animal - Rabbit) from Invitrogen
8. Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
9. Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
10. Vaginal Keratinocyte Progenitors, Rabbit from CHEMICON
11. Dermal Fibroblasts, Rabbit from CHEMICON
Adipocyte Lipolysis Colorimetric Assay Kit from Zen-Bio, Inc.
Coating-3 Reagent, 35mL from Caliper Life Sciences
Calcium Flux Agonist Chip, 4-Sipper (coated) from Caliper Life Sciences
Experion Pro260 Chips, 10 from Bio-Rad
Biology Products:
(Date:11/4/2009)... , WALL, N.J., Oct. 26 /PRNewswire-FirstCall/...d: BKYI), a leader in finger-based biometric ident... identity solutions at the AABB TXPO conference be... October 25-27 2009. BIO-key will provide hands-on...entification technology in booth #424. Also, at 5 ...
(Date:11/4/2009)... , , CHAPEL HILL Scientists at the Universi...cine and the University of California, San Francis...nique to predict new target diseases for existing ...al method that compares how similar the structures... binding partners -- known as ligands -- of diseas...
(Date:11/4/2009)... , SEATTLE, Nov. 4 Glencoe So...scopy Environment (OME) Consortium ( http://openm...ration with the American Society of Cell Biology,s...ibrary." The ASCB has been awarded a $2.5M stimulu...s (NIH) Grand Opportunities program, as part of th...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Study points to new uses, unexpected side effects of already existing drugs 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2California Cancer Specialists Medical Group Inc Opens Outpatient Cancer Center in South Pasadena Calif With Renowned Medical Staff State of the 53860 1California Cancer Specialists Medical Group Inc Opens Outpatient Cancer Center in South Pasadena Calif With Renowned Medical Staff State of the 53860 2PharmatrophiX Initially Funded by the Alzheimers Drug Discovery Foundation Announces Exclusive Global Collaboration with Elan 13417 1PharmatrophiX Initially Funded by the Alzheimers Drug Discovery Foundation Announces Exclusive Global Collaboration with Elan 13417 2PharmatrophiX Initially Funded by the Alzheimers Drug Discovery Foundation Announces Exclusive Global Collaboration with Elan 13417 3Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium 53855 1Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium 53855 2
...rchers at Columbia University’s Mailman School of ...tection of liver cancer. Using DNA isolated from ...sts examined changes in certain tumor suppressor g...t of liver carcinomas. This is the first study to ...ly detection of liver cancer in high-risk populati...
...ning synthetic chemistry techniques with a knowled...tists have been able to produce an exciting class ...-green algae. , This accomplishment is expected t...ing drugs for use in clinical trials. , In a st...the journal ACS Chemical Biology, a scientific tea...
...cent years, researchers have worked to develop a n...tumors. Cancer vaccines are not intended to preven...sponses to preexisting tumors. Unlike traditional ...y and, potentially, a high degree of efficacy. , T...o directly stimulate one of the body,s most critic...
Other Biology News:Mailman School of Public Health researchers report blood DNA can be early predictor of liver cancer 2Turning green gunk to gold, anti-cancer gold 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 3
(Date:11/6/2009)...if., Nov. 6 Intarcia Therapeutics,...A 650 (DUROS® continuous delivery of exenatid... the Ninth Annual Diabetes Technology Meeting in S....com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, C...TCA 650 Lowers Plasma Glucose, HbA1c and Reduces W...
(Date:11/5/2009)..., Md., Nov. 5 GenVec, In...results for the third quarter ended September 30, ...$0.04 per share) for the three months ended Septem...n ($0.08 per share) in the comparable quarter of 2... GenVec,s net loss was $14.1 million ($0.15 per sh...
(Date:11/5/2009)...ov. 5 Imagenetix, Inc. (...lliam Spencer, President and CEO of Imagenetix, wi...nual LD MICRO Conference on Thursday, December 3rd...s. ,, About LD MICRO ,, LD MICRO is a by-inv...ng undervalued companies in the micro-cap space. S...
(Date:11/5/2009)... Nov. 5 Transgenomic, In...ncial results for the quarter ended September 30, ...d in the tables that follow. ,, Third Quarter ...6,000 or $0.01 per share for the third quarter of ...1 per share for the third quarter of 2008. ,, ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7